Vivos Therapeutics reports Q2/Q3 2022 revenue $4.2M each; appliance units up 28% and 20% YoY

Vivos Therapeutics, Inc.

Q2 revenue $4.2M, Q3 revenue $4.2M; net income not disclosed due to revenue recognition policy change.
Appliance arches sold: 3,321 (Q2, +28% YoY) and 3,057 (Q3, +20% YoY).
Gross margin fell to 62% (Q2) and 59% (Q3) from 81% and 70% in prior year periods.
Cash and equivalents $6.7M at Sept 30, 2022; company targeting positive cash flow in 12-18 months.
Operational highlights include TGA clearances for oral appliances in Australia and strategic billing partnership with Nexus Dental.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vivos Therapeutics, Inc. reported the second quarter of 2022 results: revenue $4.2 million.

Period: the second quarter of 2022
Revenue: $4.2 million
Result: reported results

Exact text from the filing

Revenue was $4.2 million for the second quarter of 2022 and $7.8 million for the six months ended June 30, 2022, compared to $4.5 million and $7.9 million for the three and six months ended June 30, 2021, respectively, which in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Vivos Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million.

Period: the third quarter of 2022
Revenue: $4.2 million
Result: reported results

Exact text from the filing

Revenue was $4.2 million for the third quarter of 2022 and $12.1 million for the nine months ended September 30, 2022, compared to $4.5 million and $12.5 million for the three and nine months ended September 30, 2021, respectively, which similarly in part reflects a deferral of a portion of revenue into future periods under Vivos’ new revenue recognition policies;

View on SEC.gov

Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-036001

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.